AIHealthcare

Lila Sciences is a Flagship Pioneering-incubated AI-for-science company building a “scientific superintelligence” platform and AI Science Factories: autonomous laboratories combining AI models, robotics, and experimental instrumentation. Its stated scope spans life, chemical, and materials sciences, including applications relevant to drug discovery and life-science R&D; it is not described in the available sources as a clinical-care or healthcare-delivery AI company. The company was founded in Flagship Pioneering’s labs in 2023 and publicly unveiled in March 2025. Its reported market position is an early-stage, well-capitalized AI-for-science/autonomous-lab platform company rather than a product-specific healthcare AI vendor. Lila announced $200M in committed seed capital in March 2025 and subsequently disclosed a $350M Series A, bringing disclosed total capital raised to $550M. Reuters reported that the Series A extension put its valuation above $1.3B. Key disclosed leaders include co-founder and CEO Geoff von Maltzahn, CTO and Head of AI Research Andrew Beam, and Chief Scientist George Church.